Abstract Library

#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board

Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Viol F, Sipos B, Amin T, Fahl M, Grabowski P,

Keywords: Neuroendocrine neoplasms, Personalized therapy, Preclinical in vitro models, Mutational based targeted therapy,

#2964 Personalized Therapy in a Case of Esophageal NEC Based on Tumor Genome Sequencing

Introduction: High-grade esophageal neuroendocrine carcinomas (NEC) constitute a rare subgroup of neuroendocrine neoplasms, with a particularly aggressive behaviour and unfavourable prognosis. To date, there are no validated biomarkers for personalized therapy and cytotoxic chemotherapy remains the standard of care. However, tumor genome sequencing may help improve NEC molecular landscape knowledge in order to identify novel targets for an individualized approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: La Salvia A

Authors: La Salvia A, Espinosa Olarte P, Modrego Sanchez A, Riesco Martinez M, Garcia Carbonero R,

Keywords: Esophageal neuroendocrine carcinoma, tumor genome sequencing, immunotherapy, tumor burden, personalized therapy,

#1347 Evaluation of the Somatostatin, CXCR4 Chemokine and Endothelin A Receptor Expression in a Large Series of Paragangliomas

Introduction: Paragangliomas are predominantly benign tumors, but in some cases invasive growth and also metastasis is observed. Given the limited number of nonsurgical treatment options, novel target structures for diagnostics and therapy of this tumor entity are urgently needed.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Kaemmerer D

Authors: Kaemmerer D, Sänger J, Arsenic R, D'Haese J, Neumann J,

Keywords: paraganglioma, somatostatin, CXCR4,

#1008 STZ-Based Chemotherapy is Associated with Durable Response Rate in Pancreatic NET as 1st or 2nd Line Treatment

Introduction: The role of chemotherapy for pancreatic neuroendocrine tumors (pNETs) is controversially discussed. Objective response rates (RR) with streptozocin (STZ)-based chemotherapy are variable. Novel targeted drugs have recently been approved.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Dilz L

Authors: Dilz L, Denecke T, Arsenic R, Steffen I, Pape U,

Keywords: pancreatic NET, Ki-67, chemotherapy, streptozotocin,

#675 Olfactory Receptor 51E1 is a Potential Novel Target for Diagnosis and Treatment of Somatostatin Receptor Negative Lung Carcinoid Patients

Introduction: Somatostatin receptor (SSTR) expression may be used for diagnosis and therapy of lung carcinoids. However, novel targets are requested.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Cui T

Authors: Cui T, Giandomenico V, Öberg K, Pelosi G, Tsolakis A,

Keywords: olfactory receptor 51E1, somatostatin receptor, lung carcinoids, novel target, OctreoScan,